Ponatinib-d8

• Description:

  Ponatinib-d8 (AP24534-d8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

• Product Name Alternative:

  AP24534-d8

• UNSPSC:

  12352005

• Hazard Statement:

  H302+H312+H332-H315-H319

• Target:

  Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.91

• Solubility:

  1 M HCl : 50mg/mL (ultrasonic; adjust pH to 1 with HCl) |10 mM in DMSO|DMSO : 25mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C (NC1=CC=C (CN2C ([2H]) ([2H]) C ([2H]) ([2H]) N (C) C ([2H]) ([2H]) C2 ([2H]) [2H]) C (C (F) (F) F) =C1) C3=CC=C (C) C (C#CC4=CN=C5C=CC=NN54) =C3

• Molecular Formula:

  C29H19D8F3N6O

• Molecular Weight:

  540.61

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501

• References & Citations:

  [1]O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16 (5), 401-412.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• Isoform:

  PDGFRα; VEGFR2/KDR/Flk-1

• CAS Number:

  1562993-37-6